Answer
Baricitinib is indicated from 2 years of age for moderate to severe atopic dermatitis in patients who are candidates for systemic therapy.
Sources for this answer
- Baricitinib LillyEli Lilly and Company Limited · emc · SmPC §4.1 Therapeutic Indications · Version 6Document updated
Sources checked